CTOs on the Move

Arbutus Biopharma

www.arbutusbio.com

 
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Matt Addiego
Sr. Director of IT and Information Security Profile

Similar Companies

Legacy Health System

Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.

Plaxgen

Plaxgen is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comet Therapeutics

Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.

Tetra Bio-Pharma

Tetra Bio-Pharma is a multi subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Calysta Energy

Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.